Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics Inc | RCV000518486 | SCV000616131 | uncertain significance | not specified | 2017-02-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002329226 | SCV002633265 | uncertain significance | Cardiovascular phenotype | 2020-02-11 | criteria provided, single submitter | clinical testing | The p.K14430N variant (also known as c.43290A>T), located in coding exon 153 of the TTN gene, results from an A to T substitution at nucleotide position 43290. The lysine at codon 14430 is replaced by asparagine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001700139 | SCV003822195 | uncertain significance | not provided | 2020-12-22 | criteria provided, single submitter | clinical testing | |
Clinical Genetics, |
RCV001700139 | SCV001924618 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Diagnostic Laboratory, |
RCV001700139 | SCV001963550 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001700139 | SCV001979416 | uncertain significance | not provided | no assertion criteria provided | clinical testing |